Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: MYELO THERAPEUTICS GMBH
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-05-01 to 2025-01-16
Current total value of award: $6728096
Description: DEVELOPMENT OF MYELO001 AS AN ORALLY APPLIED MEDICAL COUNTERMEASURE FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME